Aclaris Therapeutics, Inc. (ACRS) stock
ACRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.92−0.08 (-2.00%)
Close on Nov 13, 2026Market cap $577.02MP/E –Yield –
Aclaris Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Aclaris Therapeutics's operating margin for the twelve months ending Sep 30, 2026 was -1414.0%. For fiscal 2025 it was -975.9%, against -758.2% the year before. The highest annual figure on record is -302.0% in fiscal 2022.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -975.9% | −217.7 |
| FY2024 | Dec 31, 2024 | -758.2% | −446.6 |
| FY2023 | Dec 31, 2023 | -311.6% | −9.5 |
| FY2022 | Dec 31, 2022 | -302.0% | +1025.1 |
| FY2021 | Dec 31, 2021 | -1327.1% | −541.6 |
| FY2020 | Dec 31, 2020 | -785.4% | +1841.9 |
| FY2019 | Dec 31, 2019 | -2627.3% | −1249.0 |
| FY2018 | Dec 31, 2018 | -1378.3% | +1851.7 |
| FY2017 | Dec 31, 2017 | -3230.0% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -1441.2% | −921.4 |
| Q2 FY2026 | Jun 30, 2026 | -1487.9% | −452.0 |
| Q1 FY2026 | Mar 31, 2026 | -1111.8% | +131.1 |
| Q4 FY2025 | Dec 31, 2025 | -1755.5% | −673.4 |
| Q3 FY2025 | Sep 30, 2025 | -519.8% | −278.9 |
| Q2 FY2025 | Jun 30, 2025 | -1035.9% | −571.2 |
| Q1 FY2025 | Mar 31, 2025 | -1242.9% | −453.4 |
| Q4 FY2024 | Dec 31, 2024 | -1082.1% | −1059.1 |
| Q3 FY2024 | Sep 30, 2024 | -240.9% | +99.3 |
| Q2 FY2024 | Jun 30, 2024 | -464.7% | +1237.5 |
| Q1 FY2024 | Mar 31, 2024 | -789.4% | +394.0 |
| Q4 FY2023 | Dec 31, 2023 | -23.0% | +352.0 |
| Q3 FY2023 | Sep 30, 2023 | -340.2% | −230.4 |
| Q2 FY2023 | Jun 30, 2023 | -1702.2% | −328.3 |
| Q1 FY2023 | Mar 31, 2023 | -1183.5% | +117.8 |
| Q4 FY2022 | Dec 31, 2022 | -375.1% | +1150.1 |
| Q3 FY2022 | Sep 30, 2022 | -109.8% | +1113.6 |
| Q2 FY2022 | Jun 30, 2022 | -1374.0% | −386.8 |
| Q1 FY2022 | Mar 31, 2022 | -1301.2% | +304.2 |
| Q4 FY2021 | Dec 31, 2021 | -1525.2% | −667.0 |
| Q3 FY2021 | Sep 30, 2021 | -1223.3% | −501.1 |
| Q2 FY2021 | Jun 30, 2021 | -987.2% | −430.9 |
| Q1 FY2021 | Mar 31, 2021 | -1605.5% | −503.4 |
| Q4 FY2020 | Dec 31, 2020 | -858.2% | +744.8 |
| Q3 FY2020 | Sep 30, 2020 | -722.2% | +1603.7 |
| Q2 FY2020 | Jun 30, 2020 | -556.3% | +4364.7 |
| Q1 FY2020 | Mar 31, 2020 | -1102.1% | +1039.7 |
| Q4 FY2019 | Dec 31, 2019 | -1603.0% | −947.7 |
| Q3 FY2019 | Sep 30, 2019 | -2325.9% | −417.0 |
| Q2 FY2019 | Jun 30, 2019 | -4921.0% | −4051.1 |
| Q1 FY2019 | Mar 31, 2019 | -2141.8% | +626.4 |
| Q4 FY2018 | Dec 31, 2018 | -655.3% | +83.4 |
| Q3 FY2018 | Sep 30, 2018 | -1908.9% | +833.2 |
| Q2 FY2018 | Jun 30, 2018 | -869.9% | – |
| Q1 FY2018 | Mar 31, 2018 | -2768.2% | – |
| Q4 FY2017 | Dec 31, 2017 | -738.7% | – |
| Q3 FY2017 | Sep 30, 2017 | -2742.1% | – |
See a number that looks wrong?